Nanodisks derived from amphotericin B lipid complex

Journal of Pharmaceutical Sciences

Volumn 97, Issue 10, 2008, Pages 4425-4432

  Tufteland, Megan ^a   Ren, Gang ^b   Ryan, Robert O ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aerosols; Amphotericin B; Amphotericin B lipid complex; Apolipoprotein A I; Drug transport; Nanodisk; Nanoparticles; Phospholipid; Proteins; Solubility

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; APOLIPOPROTEIN A1; NANODISK; NANOPARTICLE; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CULTURE MEDIUM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG TRANSPORT; ELECTRON MICROSCOPY; FUNGUS CULTURE; GROWTH INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; SACCHAROMYCES CEREVISIAE; SPECTROSCOPY;

EID: 55749092466     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21325     Document Type: Article

References (25)

1. Dupont B. 2002. Overview of the lipid formulations of amphotericin B. J Antimicrob Chem 49:31-36.
2. Janoff AS, Boni LT, Popescu MC, Minchey SR, Cullis PR, Madden TD, Taraschi T, Gruner SM, Shyamsunder E, Tate MW, Mendelsohn R, Bonner D. 1988. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci USA 85:6122-6126.
3. Oda MN, Hargreaves PL, Beckstead JA, Redmond KA, van Antwerpen R, Ryan RO. 2005. Reconstituted high-density lipoprotein enriched with the polyene antibiotic, amphotericin B. J Lipid Res 47:260-267.
4. Pownall HJ, Massey JB, Kusserow SK, Gotto AM. 1978. Kinetics of lipid-protein interactions: Interaction of apolipoprotein A-I from human plasma high density lipoproteins with phosphatidylcholines. Biochemistry 17:1183-1188.
5. Martin DD, Budamagunta MS, Ryan RO, Voss JC, Oda MN. 2006. Apolipoprotein A-I assumes a "looped belt" conformation on reconstituted high density lipoprotein. J Biol Chem 281:20418-20426.
6. Nelson KG, Bishop JV, Ryan RO, Titus R. 2006. Nanodisk-associated amphotericin B clears Leishmania major cutaneous infection in susceptible BALB/c mice. Antimicrob Agents Chemother 50:1238-1244.
7. Ryan RO, Forte TM, Oda MN. 2003. Optimized bacterial expression of human apolipoprotein A-I. Protein Exp Purif 27:98-103.
8. Tufteland M, Pesavento JB, Bermingham RL, Hoeprich PD Jr, Ryan RO. 2007. Peptide stabilized amphotericin B nanodisks. Peptides 28:741-746.
9. Bolard J, Legrand P, Heitz F, Cybulska B. 1991. One-sided action of amphotericinBon cholesterol-containing membranes is determined by its self-association in the medium. Biochemistry 30:5707-5715.
10. Ludtke SJ, Baldwin PR, Chiu W. 1999. EMAN: Semiautomated software for high-resolution single-particle reconstructions. J Struct Biol 128:82-97.
11. Pfaller MA, Barry AL. 1994. Evaluation of a novel colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates. J Clin Microbiol 32:1992-1996.
12. Tiballi RN, He X, Zarins LT, Revankar SG, Kauffman CA. 1995. Use of a colorimetric system for yeast susceptibility testing. J Clin Microbiol 33:915-917.
13. Wong-Beringer A, Lambros MP, Beringer PM, Johnson DL. 2005. Suitability of caspofungin for aerosol delivery: Physiochemical profiling and nebulizer choice. Chest 128:3711-3716.
14. Weber A, Morlin G, Cohen M, Williams-Warren J, Ramsey B, Smith A. 1997. Effect of nebulizer type and antibiotic concentration on device performance. Pediatr Pulmonol 23:249-260.
15. Hargreaves PL, Nguyen TS, Ryan RO. 2006. Spectroscopic studies of amphotericin B solubilized in nanoscale bilayer membranes. Biochim Biophys Acta 1758:38-44.
16. Ernst C, Grange J. 1981. Structure of amphotericin B aggregates as revealed by UV and CD spectroscopies. Biopolymers 20:1575-1588.
17. Carrillo-Munoz AJ, Ruesga M, Brio S, del Valle O, Rodriguez V, Santos P, Hernandez-Molina JM, Canton E, Peman J, Guarro J, Quindos G. 2002. Comparison of in vitro Antifungal Activities of Amphotericin B Lipid Complex with Itraconazole against 708 Clinical Yeast Isolates and Opportunistic Moulds Determined by National Committee for Clinical Laboratory Standards Methods M27-A and M38-P. Chemotherapy 48:224-231.
18. Janknegt R, de Marie S, Bakker-Woudenberg IA, Crommelin DJ. 1992. Liposomal and lipid formulations of amphotericin B. Clin Pharmacokinet 23:279-291.
19. Boswell GW, Buell D, Bekersky I. 1998. AmBisome (liposomal amphotericin B): A comparative review. J Clin Pharmacol 38:583-592.
20. Adler-Moore JP, Proffitt RT. 1993. Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. J Liposome Res 3:429-450.
21. Wasan KM, Rosenblum MG, Cheung L, Lopez-Berestein G. 1994. Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrob Agents Chemother 38:223-227.
22. Nguyen T-S, Weers PMM, Raussens V, Wang Z, Ren G, Sulchek T, Hoeprich PD Jr, Ryan RO. 2008. Amphotericin B induces interdigitation of apolipoprotein stabilized nanodisk bilayers. Biochim Biophys Acta, Oct. 16, 2007.
23. Kiss RS, Weers PM, Narayanaswami V, Cohen J, Kay C, Ryan RO. 2003. Structure-guided protein engineering modulates helix bundle exchangeable apolipoprotein properties. J Biol Chem 278:21952-21959.
24. O'Riordan TG. 2002. Formulations and nebulizer performance. Respir Care 47:1305-1312.
25. Yao Z, Liao W. 2006. Fungal respiratory disease. Curr Opin Pulm Med 12:222-227.